Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation
Open Access
- 1 January 2018
- journal article
- research article
- Published by XMLink in Journal of Korean Medical Science
- Vol. 33 (24) , e167
Abstract
Kim SH, et al. J Korean Med Sci. 2018 May;33(24):e167. https://doi.org/10.3346/jkms.2018.33.e167Keywords
Funding Information
- National Cancer Center (1120320)
This publication has 24 references indexed in Scilit:
- European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomasThe Lancet Oncology, 2017
- Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomideNeuro-Oncology, 2016
- International retrospective study of over 1000 adults with anaplastic oligodendroglial tumorsNeuro-Oncology, 2011
- An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology settingCancer Chemotherapy and Pharmacology, 2011
- Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumorsNeuro-Oncology, 2010
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent GlioblastomaJournal of Clinical Oncology, 2009
- New (alternative) temozolomide regimens for the treatment of gliomaNeuro-Oncology, 2009
- Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma.Oncology Reports, 2007
- Salvage temozolomide for prior temozolomide respondersCancer, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005